Ebrahim Abbasi
ABSTRACT Insects are emerging as valuable biomedical agents due to their unique biological properties, offering novel approaches for pathogen detection, drug development, and wound management. This review examines recent advancements in insect‐based medical applications, particularly in the context of antimicrobial resistance (AMR). A comprehensive analysis of studies on insect‐derived bioactive compounds, insect biosensors, larval therapy, and insect microbiota was conducted to evaluate their efficacy and clinical potential. Findings indicate that insect‐based biosensors, leveraging insect olfactory systems, enable non‐invasive detection of diseases, such as cancer and tuberculosis. Bioactive compounds, including melittin and anophelin, demonstrate potent antimicrobial activity, presenting promising alternatives to conventional antibiotics. Maggot debridement therapy effectively promotes chronic wound healing, whereas insect microbiota offers new antimicrobial agents to combat resistant pathogens. Despite these advancements, challenges related to standardization, scalability, and patient acceptance remain. Future research should focus on genetic engineering, optimized drug delivery systems, and regulatory frameworks to facilitate clinical translation. Insect‐based medical applications represent a promising frontier in biomedicine, necessitating interdisciplinary collaboration for their successful integration into healthcare.